Podcasts about biopsies

This episode of the podcast welcomes Dr. Kelly Keating, DACVP, DACVD. Dr. Keating sees clinical dermatology cases in Las Vegas and reviews dermatopathology. So, she has experience collecting the biopsy samples herself and reading them!Dr. Keating provides insight on how to maximize your histopathology findings and work with your dermatopathologist to get a diagnosis. Nobody wants to get back non-specific inflammation!You can go to https://www.animaldermatology.com/dermatopathology-services if you are interested in submitting to Animal Dermatopathology Services!TIMESTAMPS00:00 Intro01:13 Most common mistakes you see with submissions to skin biopsy?04:46 How much does having a submission of history help you when you do get a sample?09:21 Tips for general practitioners who are submitting biopsies12:04 Tips for mass removals14:46 Site selection18:28 Biopsy an ulcer20:14 Preferred withdrawal time24:25 How often do you see infections covering up what you need to see?27:40 What are special stains?30:05 Tissue Culture explanation 33:18 Biopsy Ear Tips35:10 Where people can send Dr. Keating samples36:47 Outro

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Sumanth Reddy discuss small vessel primary CNS vasculitis. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200397 

May 30, 2025 In this episode, Mark and Scott address upcoming significant changes to the prostate biopsy codes and provide guidance on correctly applying modifiers 25 and 59 when billing procedure 51798 and an E/M service. They also discuss coding considerations for the emerging practice of robotic-assisted vasectomies.PRS Coding and Reimbursement HubAccess the HubJelmyto Coding and Reimbursement PageUpper Track Urothelial Cancer (UTUC) Coding and Reimbursement PageFree Kidney Stone Coding CalculatorDownload NowPRS Billing and Other Services - Book a Call with Mark Painter or Marianne DescioseClick Here to Get More Information and Request a Quote Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.https://www.prsnetwork.com/joinuptp Click Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Dr. Justin Abbatemarco talks with Drs. Sumanth Reddy and Jeffrey Gelfand about the complexities of small vessel predominant primary CNS vasculitis, clinical features, and the impact of early intensive immunosuppressive therapy on remission.  Read the related article in Neurology® Neuroimmunology & Neuroinflammation.  Disclosures can be found at Neurology.org. 

Drs Park and Malla began by talking through the clinical utility of ctDNA in patients with stage II and III colon cancer. Dr Malla referenced the DYNAMIC (ACTRN12615000381583) and observational BESPOKE CRC (NCT04264702) trials, noting that ctDNA serves as a prognostic biomarker for recurrence and is increasingly used to guide post-surgical surveillance.

Download the Cancer Terrain TrackerUnderstanding Cancer: Inherited Risks, Biopsy Concerns, and the Impact of EnvironmentThis episode delves into common questions about cancer, addressing misconceptions about genetic predispositions and the impact of environmental factors. Topics include the role of epigenetics, the potential risks of biopsies, the concept of metabolic cancer theory, and how routine labs might hint at early cancer signs. The speaker emphasizes the importance of becoming one's own health advocate and understanding the broader context of cancer development and prevention. Additionally, various emerging diagnostic technologies are discussed as potentially safer alternatives to traditional biopsies.00:00 Introduction: The Reality of Cancer01:43 Understanding Genetic Risks03:12 Epigenetics and Environmental Factors07:18 Inherited Trauma and Cancer09:43 Biopsies and Cancer Spread21:55 Metabolic vs. Genetic Theories of Cancer26:34 Detecting Cancer in Routine Labs30:50 Conclusion and Resources

Joining us today is Dr. Robert Convissar, a general dentist who has performed thousands of oral cancer exams and hundreds of biopsies. He will share his approach to screening, his clinical insights, and some valuable tips that can dramatically improve our ability to detect oral cancer at its earliest, most treatable stages. Dr. Convissar has authored over twenty peer-reviewed papers and 7 laser textbooks. He has delivered close to 400 continuing education programs worldwide.

If we're to live eternally, the ultimate biopsy of our character taken at the end of the age must reveal consistent Christian practice

Imagine a future where you go in for your annual check-up and get a blood test to screen for cancer, in the same way you currently get screened for high cholesterol or diabetes. Some hope that liquid biopsy technology could eventually make this possible — but it has a long way to go before it gets to that point. Laborastories host Dr. Anthony Killeen sits down with Dr. Christina Lockwood for a realistic outlook on this exciting technology and an overview of the challenges that must be overcome before it's put into routine use. With special guest: Dr. Christina Lockwood Hosted by: Dr. Anthony Killeen

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial.This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risks, patient experiences, and the potential implications for clinical practice and health policy.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00100-7/fulltext?dgcid=buzzsprout_tlv_podcast_30-04-25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the updated recommendations and topics such as when SLNB can be omitted, when ALND is indicated, radiation and systemic treatment decisions after SLNB omission, and the role of SLNB in special circumstances. We discuss the importance of shared decision-making and other ongoing and future de-escalation trials that will expand knowledge in this space. Read the full guideline update, “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update” at www.asco.org/breast-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-00099       Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Ko Un "Clara" Park from Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dr. Mylin Torres from Glenn Family Breast Center at Winship Cancer Institute of Emory University, co-chairs on “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you, it's a pleasure to be here. Brittany Harvey: And before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Torres and Dr. Park, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To start us off, Dr. Torres, what is the scope and purpose of this guideline update on the use of sentinel lymph node biopsy in early-stage breast cancer? Dr. Mylin Torres: The update includes recommendations incorporating findings from trials released since our last published guideline in 2017. It includes data from nine randomized trials comparing sentinel lymph node biopsy alone versus sentinel lymph node biopsy with a completion axillary lymph node dissection. And notably, and probably the primary reason for motivating this update, are two trials comparing sentinel lymph node biopsy with no axillary surgery, all of which were published from 2016 to 2024. We believe these latter two trials are practice changing and are important for our community to know about so that it can be implemented and essentially represent a change in treatment paradigms. Brittany Harvey: It's great to hear about these practice changing trials and how that will impact these recommendation updates. So Dr. Park, I'd like to start by reviewing the key recommendations across all of these six overarching clinical questions that the guideline addressed. So first, are there patients where sentinel lymph node biopsy can be omitted? Dr. Ko Un "Clara" Park: Yes. The key change in the current management of early-stage breast cancer is the inclusion of omission of sentinel lymph node biopsy in patients with small, less than 2 cm breast cancer and a negative finding on preoperative axillary ultrasound. The patients who are eligible for omission of sentinel lymph node biopsy according to the SOUND and INSEMA trial are patients with invasive ductal carcinoma that is size smaller than 2 cm, Nottingham grades 1 and 2, hormone receptor-positive, HER2-negative in patients intending to receive adjuvant endocrine therapy, and no suspicious lymph nodes on axillary ultrasound or if they have only one suspicious lymph node, then the biopsy of that lymph node is benign and concordant according to the axillary ultrasound findings. The patients who are eligible for sentinel lymph node biopsy omission according to the SOUND and INSEMA trials were patients who are undergoing lumpectomy followed by whole breast radiation, especially in patients who are younger than 65 years of age. For patients who are 65 years or older, they also qualify for omission of sentinel lymph node biopsy in addition to consideration for radiation therapy omission according to the PRIME II and CALGB 9343 clinical trials. And so in those patients, a more shared decision-making approach with the radiation oncologist is encouraged. Brittany Harvey: Understood. I appreciate you outlining that criteria for when sentinel lymph node biopsy can be omitted and when shared decision making is appropriate as well. So then, Dr. Torres, in those patients where sentinel lymph node biopsy is omitted, how are radiation and systemic treatment decisions impacted? Dr. Mylin Torres: Thank you for that question. I think there will be a lot of consternation brought up as far as sentinel lymph node biopsy and the value it could provide in terms of knowing whether that lymph node is involved or not. But as stated, sentinel lymph node biopsy actually can be safely omitted in patients with low risk disease and therefore the reason we state this is that in both SOUND and INSEMA trial, 85% of patients who had a preoperative axillary ultrasound that did not show any signs of a suspicious lymph node also had no lymph nodes involved at the time of sentinel node biopsy. So 85% of the time the preoperative ultrasound is correct. So given the number of patients where preoperative ultrasound predicts for no sentinel node involvement, we have stated within the guideline that radiation and systemic treatment decisions should not be altered in the select patients with low risk disease where sentinel lymph node biopsy can be omitted. Those are the patients who are postmenopausal and age 50 or older who have negative findings on preoperative ultrasound with grade 1 or 2 disease, small tumors less than or equal to 2 cm, hormone receptor-positive, HER2-negative breast cancer who undergo breast conserving therapy. Now, it's important to note in both the INSEMA and SOUND trials, the vast majority of patients received whole breast radiation. In fact, within the INSEMA trial, partial breast irradiation was not allowed. The SOUND trial did allow partial breast irradiation, but in that study, 80% of patients still received whole breast treatment. Therefore, the preponderance of data does support whole breast irradiation when you go strictly by the way the SOUND and INSEMA trials were conducted. Notably, however, most of the patients in these studies had node-negative disease and had low risk features to their primary tumors and would have been eligible for partial breast irradiation by the ASTRO Guidelines for partial breast treatment. So, given the fact that 85% of patients will have node-negative disease after a preoperative ultrasound, essentially what we're saying is that partial breast irradiation may be offered in these patients where omission of sentinel node biopsy is felt to be safe, which is in these low risk patients. Additionally, regional nodal irradiation is something that is not indicated in the vast majority of patients where omission of sentinel lymph node biopsy is prescribed and recommended, and that is because very few of these patients will actually end up having pathologic N2 disease, which is four or more positive lymph nodes. If you look at the numbers from both the INSEMA and the SOUND trial, the number of patients with pathologic N2 disease who did have their axilla surgically staged, it was less than 1% in both trials. So, in these patients, regional nodal irradiation, there would be no clear indication for that more aggressive and more extensive radiation treatment. The same principles apply to systemic therapy. As the vast majority of these patients are going to have node-negative disease with a low risk primary tumor, we know that postmenopausal women, even if they're found to have one to three positive lymph nodes, a lot of the systemic cytotoxic chemotherapy decisions are driven by genomic assay score which is taken from the primary tumor. And therefore nodal information in patients who have N1 disease may not be gained in patients where omission of sentinel lymph node biopsy is indicated in these low risk patients. 14% of patients have 1 to 3 positive lymph nodes in the SOUND trial and that number is about 15% in the INSEMA trial. Really only the clinically actionable information to be gained is if a patient has four or more lymph nodes or N2 disease in this low risk patient population. So, essentially when that occurs it's less than 1% of the time in these patients with very favorable primary tumors. And therefore we thought it was acceptable to stand by a recommendation of not altering systemic therapy or radiation recommendations based on omission of sentinel nodes because the likelihood of having four more lymph nodes is so low. Dr. Ko Un "Clara" Park: I think one thing to add is the use of CDK4/6 inhibitors to that and when we look at the NATALEE criteria for ribociclib in particular, where node-negative patients were included, the bulk majority of the patients who were actually represented in the NATALEE study were stage III disease. And for stage I disease to upstage into anatomic stage III, that patient would need to have pathologic N2 disease. And as Dr. Torres stated, the rate of having pathologic N2 disease in both SOUND and INSEMA studies were less than 1%. And therefore it would be highly unlikely that these patients would be eligible just based on tumor size and characteristics for ribociclib. So we think that it is still safe to omit sentinel lymph node biopsy and they would not miss out, if you will, on the opportunity for CDK4/6 inhibitors. Brittany Harvey: Absolutely. I appreciate you describing those recommendations and then also the nuances of the evidence that's underpinning those recommendations, I think that's important for listeners. So Dr. Park, the next clinical question addresses patients with clinically node negative early stage breast cancer who have 1 or 2 sentinel lymph node metastases and who will receive breast conserving surgery with whole breast radiation therapy. For these patients, is axillary lymph node dissection needed? Dr. Ko Un "Clara" Park: No. And this is confirmed based on the ACOSOG Z0011 study that demonstrated in patients with 1 to 3 positive sentinel lymph node biopsy when the study compared completion axillary lymph node dissection to no completion axillary lymph node dissection, there was no difference. And actually, the 10-year overall survival as reported out in 2017 and at a median follow up of 9.3 years, the overall survival again for patients treated with sentinel lymph node biopsy alone versus those who were treated with axillary lymph node dissection was no different. It was 86.3% in sentinel lymph node biopsy versus 83.6% and the p-value was non-inferior at 0.02. And so we believe that it is safe for the select patients who are early stage with 1 to 2 positive lymph nodes on sentinel lymph node biopsy, undergoing whole breast radiation therapy to omit completion of axillary lymph node dissection. Brittany Harvey: Great, I appreciate you detailing what's recommended there as well. So then, to continue our discussion of axillary lymph node dissection, Dr. Torres, for patients with nodal metastases who will undergo mastectomy, is axillary lymph node dissection indicated? Dr. Mylin Torres: It's actually not and this is confirmed by two trials, the AMAROS study as well as the SENOMAC trial. And in both studies, they compared a full lymph node dissection versus sentinel lymph node biopsy alone in patients who are found to have 1 to 2 positive lymph nodes and confirmed that there was no difference in axillary recurrence rates, overall survival or disease-free survival. What was shown is that with more aggressive surgery completion axillary lymph node dissection, there were higher rates of morbidity including lymphedema, shoulder pain and paresthesias and arm numbness, decreased functioning of the arm and so there was only downside to doing a full lymph node dissection. Importantly, in both trials, if a full lymph node dissection was not done in the arm that where sentinel lymph node biopsy was done alone, all patients were prescribed post mastectomy radiation and regional nodal treatment and therefore both studies currently support the use of post mastectomy radiation and regional nodal treatment when a full lymph node dissection is not performed in these patients who are found to have N1 disease after a sentinel node biopsy. Brittany Harvey: Thank you. And then Dr. Park, for patients with early-stage breast cancer who do not have nodal metastases, can completion axillary lymph node dissection be omitted? Dr. Ko Un "Clara" Park: Yes, and this is an unchanged recommendation from the earlier ASCO Guidelines from 2017 as well as the 2021 joint guideline with Ontario Health, wherein patients with clinically node-negative early stage breast cancer, the staging of the axilla can be performed through sentinel lymph nodal biopsy and not completion axillary lymph node dissection. Brittany Harvey: Understood. So then, to wrap us up on the clinical questions here, Dr. Park, what is recommended regarding sentinel lymph node biopsy in special circumstances in populations? Dr. Ko Un "Clara" Park: One key highlight of the special populations is the use of sentinel lymph node biopsy for evaluation of the axilla in clinically node negative multicentric tumors. While there are no randomized clinical trials evaluating specifically the role of sentinel lymph nodal biopsy in multicentric tumors, in the guideline, we highlight this as one of the safe options for staging of the axilla and also for pregnant patients, these special circumstances, it is safe to perform sentinel lymph node biopsy in pregnant patients with the use of technetium - blue dye should be avoided in this population. In particular, I want to highlight where sentinel lymph node biopsy should not be used for staging of the axilla and that is in the population with inflammatory breast cancer. There are currently no studies demonstrating that sentinel lymph node biopsy is oncologically safe or accurate in patients with inflammatory breast cancer. And so, unfortunately, in this population, even after neoadjuvant systemic therapy, if they have a great response, the current guideline recommends mastectomy with axillary lymph node dissection. Brittany Harvey: Absolutely. I appreciate your viewing both where sentinel lymph node can be offered in these special circumstances in populations and where it really should not be used. So then, Dr. Torres, you talked at the beginning about how there's been these new practice changing trials that really impacted these recommendations. So in your view, what is the importance of this guideline update and how does it impact both clinicians and patients? Dr. Mylin Torres: Thank you for that question. This update and these trials that inform the update represent a significant shift in the treatment paradigm and standard of care for breast cancer patients with early-stage breast cancer. When you think about it, it seems almost counterintuitive that physicians and patients would not want to know if a lymph node is involved with cancer or not through sentinel lymph node biopsy procedure. But what these studies show is that preoperative axillary ultrasound, 85% of the time when it's negative, will correctly predict whether a sentinel lymph node is involved with cancer or not and will also be negative. So if you have imaging that's negative, your surgery is likely going to be negative. Some people might ask, what's the harm in doing a sentinel lymph node biopsy? It's important to recognize that upwards of 10% of patients, even after sentinel lymph node biopsy will develop lymphedema, chronic arm pain, shoulder immobility and arm immobility. And these can have a profound impact on quality of life. And if there is not a significant benefit to assessing lymph nodes, particularly in someone who has a preoperative axillary ultrasound that's negative, then why put a patient at risk for these morbidities that can impact them lifelong? Ideally, the adoption of omission of sentinel lymph node biopsy will lead to more multidisciplinary discussion and collaboration in the preoperative setting especially with our diagnostic physicians, radiology to assure that these patients are getting an axillary ultrasound and determine how omission of sentinel lymph node biopsy may impact the downstream treatments after surgery, particularly radiation and systemic therapy decisions, and will be adopted in real world patients, and how clinically we can develop a workflow where together we can make the best decisions for our patients in collaboration with them through shared decision making. Brittany Harvey: Absolutely. It's great to have these evidence-based updates for clinicians and patients to review and refer back to. So then finally, Dr. Park, looking to the future, what are the outstanding questions and ongoing trials regarding sentinel lymph node biopsy in early-stage breast cancer? Dr. Ko Un "Clara" Park: I think to toggle on Dr. Torres's comment about shared decision making, the emphasis on that I think will become even more evident in the future as we incorporate different types of de-escalation clinical studies. In particular, because as you saw in the SOUND and INSEMA studies, when we de-escalate one modality of the multimodality therapy, i.e., surgery, the other modalities such as radiation therapy and systemic therapy were “controlled” where we were not de-escalating multiple different modalities. However, as the audience may be familiar with, there are other types of de-escalation studies in particular radiation therapy, partial breast irradiation or omission of radiation therapy, and in those studies, the surgery is now controlled where oftentimes the patients are undergoing surgical axillary staging. And conversely when we're looking at endocrine therapy versus radiation therapy clinical trials, in those studies also the majority of the patients are undergoing surgical axillary staging. And so now as those studies demonstrate the oncologic safety of omission of a particular therapy, we will be in a position of more balancing of the data of trying to select which patients are the safe patients for omission of certain types of modality, and how do we balance whether it's surgery, radiation therapy, systemic therapy, endocrine therapy. And that's where as Dr. Torres stated, the shared decision making will become critically important. I'm a surgeon and so as a surgeon, I get to see the patients oftentimes first, especially when they have early-stage breast cancer. And so I could I guess be “selfish” and just do whatever I think is correct. But whatever the surgeon does, the decision does have consequences in the downstream decision making. And so the field really needs to, as Dr. Torres stated earlier, rethink the workflow of how early-stage breast cancer patients are brought forth and managed as a multidisciplinary team. I also think in future studies the expansion of the data to larger tumors, T3, in particular,reater than 5 cm and also how do we incorporate omission in that population will become more evident as we learn more about the oncologic safety of omitting sentinel lymph node biopsy. Dr. Mylin Torres: In addition, there are other outstanding ongoing clinical trials that are accruing patients right now. They include the BOOG 2013-08 study, SOAPET, NAUTILUS and the VENUS trials, all looking at patients with clinical T1, T2N0 disease and whether omission of sentinel lymph node biopsy is safe with various endpoints including regional recurrence, invasive disease-free survival and distant disease-free survival. I expect in addition to these studies there will be more studies ongoing even looking at the omission of sentinel lymph node biopsy in the post-neoadjuvant chemotherapy setting. And as our imaging improves in the future, there will be more studies improving other imaging modalities, probably in addition to axillary ultrasound in an attempt to accurately characterize whether lymph nodes within axilla contain cancer or not, and in that context whether omission of sentinel lymph node biopsy even in patients with larger tumors post-neoadjuvant chemotherapy may be done safely and could eventually become another shift in our treatment paradigm. Brittany Harvey: Yes. The shared decision making is key as we think about these updates to improve quality of life and we'll await data from these ongoing trials to inform future updates to this guideline. So I want to thank you both so much for your extensive work to update this guideline and thank you for your time today. Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you. Dr. Ko Un "Clara" Park: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode, Dr. Stephen Petteruti reexamines the conventional approach to prostate cancer screening, offering a perspective on when a more measured approach may be the best course of action. Many prostate cancers are slow-growing and may never pose a serious threat, yet aggressive treatments continue to be the norm. Instead of rushing into invasive procedures, Dr. Stephen explores alternative strategies, such as advanced imaging, targeted drug therapies, and lifestyle modifications that support long-term prostate health.Listen now for expert insights that will help you make informed decisions and avoid unnecessary procedures. Watch the latest episode of Intellectual Medicine Podcast — Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies.Enjoy the podcast? Subscribe and leave a 5-star review!————————————————————————————————Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website:  www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/  Instagram: https://www.instagram.com/intellectualmedicine  YouTube: https://www.youtube.com/@intellectualmedicinePersonal Website: https://drstephenpetteruti.com/Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.#ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #HealthPodcast

This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT results.  One reason FibroSIGHT is worthy of attention: This is the first time an in-depth analysis of clinical trial biopsy results is being placed at the service of clinical treatment. Another reason: Yukti states that demand for this technique could equal 163,000 cases this year, rising to one million by 2028. The interview starts with Yukti sharing information on her own academic and commercial background and how she came to this role. She describes FibroSIGHT, a service that will provide a highly accurate CRN fibrosis level for patients whose NIT results suggest no clear or consistent finding. Yukti provides practical cues on ordering the test and its reimbursement. Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit in this analysis. Roger goes on to express concern that any option requiring more biopsies will reduce the number of patients treated, particularly if having this tool encourages payers to require a biopsy as a prerequisite to treatment. He asks whether, over time, HistoIndex might be able to develop a companion analytic to improve these estimates without requiring biopsy. 

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.

When it comes to your health, are you blindly following the standard protocol—or taking control of your own decisions?In this episode, Dr. Stephen Petteruti dives into the controversial world of PSA tests, prostate biopsies, and the hidden risks behind conventional recommendations. Are these procedures truly necessary, or is there a better way to approach prostate health?Dr. Stephen challenges the status quo and explores alternative approaches that prioritize proactive health management over fear-driven decisions.Have you or someone you know faced a difficult decision about PSA tests or biopsies? Drop your thoughts in the comments—let's start the conversation!Tune in to the full episode of Intellectual Medicine Podcast —Don't Biopsy Your Prostate Until You Hear This (Part 2).Enjoy the podcast? Subscribe and leave a 5-star review! ————————————————————————————————Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website:  www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/  Instagram: https://www.instagram.com/intellectualmedicine  YouTube: https://www.youtube.com/@intellectualmedicinePersonal Brand: https://drstephenpetteruti.com/Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan. #ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #HealthPodcast

This week's topics include cell signatures in PCOS, a new technique for prostate biopsies, improving the safety of carotid endarterectomy, and long term risk after TIA.0:41 Long term risk of stroke after TIA1:39 About one in five over the next ten years2:40 Need to continue antiplatelet agents3:33 New technique for prostate biopsy4:36 Biopsy naive men5:35 Microultrasonography used6:35 Limited availability of MRI7:33 Improving safety of carotid endarterectomy8:33 Sonolysis used9:34 Safe and routinely available9:40 Single cell characterization of PCOS endometrium10:40 Cells harvested during proliferative phase11:40 PCOS causes increased risk of endometrial cancer12:54 End

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from March 22-28, 2025.

We are delighted to drop this pod just as the landmark TRANSLATE trial reads out at the EAU Annual Meeting in Madrid, with a simultaneous publication in Lancet Oncology. This is the world's largest trial of transrectal vs transperineal (TP) prostate biopsy, and reports that TP biopsy has superior cancer detection ability. Is this the end of the road for TRUS biopsy. Hosts Declan Murphy and Renu Eapen are delighted to welcome first and senior authors, Prof Richard Bryant and Dr Alastair Lamb of the University of Oxford to have a detailed discussion about TRANSLATE and what this means for prostate biopsy. `Even better on our YouTube channel Links:Lancet Oncology paperFunders: 

Did you know that prostate biopsies could do more harm than good? In this episode, Dr. Stephen Petteruti reveals why these procedures may lead to unnecessary treatments, complications, and even the spread of cancer cells. Many prostate cancers are non-aggressive and never become life-threatening—so why take the risk?Discover safer, evidence-based strategies for monitoring your prostate health without invasive procedures. Don't let fear make the decision for you—get the facts and take control of your health with confidence.Catch the full episode of Intellectual Medicine Podcast —  Think Twice Before a Prostate Biopsy: The Evidence You Need to Hear.Enjoy the podcast? Subscribe and leave a 5-star review! ————————————————————————————————Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website:  www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/  Instagram: https://www.instagram.com/intellectualmedicine  YouTube: https://www.youtube.com/@intellectualmedicinePersonal Brand: https://drstephenpetteruti.com/ #ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #HealthPodcast

Matthew Dietz, DO, MSEd joins us on OsteoBites to discuss Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children's Oncology Group Bone Tumour Committee.To advance the care and cure for patients with osteosarcoma and Ewing sarcoma it is necessary to safely improve the amount and usability of diagnostic biopsy material obtained. Indeed, it is anticipated that future osteosarcoma and Ewing sarcoma clinical trials will incorporate molecular biomarkers into treatment risk stratification underscoring the need for optimal tissue collection and processing practices.Historically open/incisional biopsies were the predominant biopsy approach; however, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and reduce recovery times but have potential limitations. Including the potential for lower tissue volumes, which can limit components of clinical care - including pathologic assessment, diagnostic accuracy, and molecular evaluations - along with the opportunity for research studies with leftover tissue (following informed consent). Additionally, once biopsy material is obtained the handling of the specimen for histologic and subsequent molecular testing requires careful timing, processing and tissue prioritization to ensure all clinical and research opportunities are preserved for the patient.To help optimize these critical elements in patient care the Children's Oncology Group convened a multidisciplinary group of clinical and scientific experts to create reference recommendations for harmonizing tissue acquisition and processing algorithms for osteosarcoma and Ewing sarcoma specimens.

An AI system trained on breast ultrasound studies showed promise in reducing false positives and biopsies by over 37% and 28%, respectively, while maintaining sensitivity, potentially aiding clinical decision-making. Second, nirsevimab demonstrated effectiveness in preventing RSV infections and hospitalizations among infants, with protection waning over time but remaining significant. Lastly, breast and colon cancer screening rates in the U.S. have surpassed pre-pandemic levels, but cervical cancer screening rates remain concerningly low, highlighting disparities in access to preventive care.

Why is insurance so expensive? Why doesn't insurance pay for everything- a biopsy shouldn't be Sophie's choice • ChatGPT is like the movie Sphere • Faith and gasoline on YouTube

Physician Ash Alizadeh has seen the future of disease diagnosis and monitoring. It is coursing through every patient's veins. Traditionally, biopsies have required invasively gathering tissue – from a lung, a liver, or a fetus. Now it's possible to look for disease without surgery. The DNA is sitting there in the bloodstream, Alizadeh tells host Russ Altman, as they preview the age of liquid biopsies on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Ash A. Alizadeh, MD/PhDConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Ash Alizadeh, a faculty member at Stanford University in Oncology and Medicine.(00:03:39) What is a Liquid Biopsy?Accessing tissues non-invasively using bodily fluids.(00:04:31) Detecting Cancer with Liquid BiopsiesHow localized cancers can be detected through blood samples.(00:06:32) The Science Behind Cancer DNA DetectionThe differences between normal and cancer DNA(00:09:51) How Liquid Biopsy Technology WorksThe technologies behind detecting cancer-related DNA differences.(00:12:36) Advances in Liquid BiopsyNew detection approaches using non-mutant molecules and RNA.(00:14:10) RNA as a Real-Time Tumor MarkerHow RNA reveals active tumor processes and drug resistance.(00:15:55) Tracking Cancer ReccurenceUsing tumor-informed panels to monitor cancer recurrence.(00:16:28)  Adapting to Tumor EvolutionWhy core mutations remain detectable despite cancer changes.(00:17:57) Stability of DNA, RNA, and MethylationComparing durability and reliability of different biomarkers.(00:20:49) Listener Question: Early Cancer DetectionDaniel Kim asks about pre-cancer detection and its potential impact.(00:24:44) Liquid Biopsy in ImmunotherapyUsing liquid biopsy to track and improve immune-based treatments.(00:27:35) Monitoring CAR T-Cell TherapyHow liquid biopsy helps assess immune cell expansion.(00:32:02) EPIC-Seq: Inferring RNA from DNAUsing DNA fragmentation to predict gene expression in tumors.(00:34:49) Targeting Tumor Support SystemsTreatment strategies disrupting the tumor microenvironment.(00:35:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Imagine detecting cancer with just a single drop of blood. In this episode of the Beautifully Broken Podcast, host Freddie Kimmel engages in a compelling conversation with Dr. Joshua Routh, MD, a distinguished expert in pathology and molecular oncology. Dr. Routh serves as the Laboratory Director for high-complexity clinical laboratories and holds the position of Associate Professor of Pathology at Midwestern University. He is also the Medical Director for Precision Epigenomics Inc., where he focuses on multi-cancer early detection tests.Together, they examine the science behind EPISEEK, discussing how it analyzes epigenetic markers in the blood to identify potential cancer signals. The conversation covers the importance of methylation in gene expression, the emotional implications of cancer testing, and who should consider getting tested. Dr. Routh emphasizes the need for patient autonomy and informed decision-making in the context of cancer screening. They also explore the advancements in multi-cancer early detection tests, focusing on the technology behind EPISEEK, its cost, and the current lack of insurance coverage. The discussion touches on the implications of abnormal test results, the importance of patient-doctor collaboration, and the need for a holistic approach to health that includes lifestyle factors. Additionally, they discuss the strengths and limitations of current cancer detection technologies and the importance of comprehensive health monitoring.Highlights1:32 Introduction: Personal Reflections on the Importance of Early Cancer Detection3:05 Understanding EpiSeek: A Breakthrough in Liquid Biopsy Technology for Cancer Detection5:40 The Science of EpiSeek: How It Works to Detect Cancer Early8:14 The Role of Methylation in Gene Expression and Its Link to Cancer Growth10:42 Gene Expression and Epigenetics: Why They Matter in Cancer Screening13:20 Interpreting Test Results: What to Do After Receiving an Abnormal Finding16:35 Who Should Get Tested? Assessing Risk Factors, Family History, and Lifestyle19:48 The Emotional Impact of Cancer Screening and the Decision Not to Test22:14 Comparing EpiSeq to Other Multi-Cancer Early Detection Tests25:52 Insurance Coverage for Multi-Cancer Tests: Current Challenges and Future Prospects29:30 Next Steps After an Abnormal Test Result: Further Screening and Actions33:40 The War on Cancer: How Lifestyle Choices Influence Cancer Risk36:15 - Evaluating the Strengths and Limitations of Current Cancer Detection Technologies40:28 - The Importance of Comprehensive Health Monitoring Beyond Single TestsUPGRADE YOUR WELLNESSEpiSeq Test: https://www.precision-epigenomics.com/episeqExclusive $50 Discount Offer (Valid Until August 1, 2025): https://www.precision-epigenomics.com/offerSilver Biotics Muscle Cream: https://www.silverbiotics.com (Use Code: BEAUTIFULLYBROKEN for Discount)Saga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Dr. Brooke Britton joins James Jacobson to demystify the mitotic index—a critical factor in understanding your dog's cancer diagnosis. Learn how this number, derived from a tumor biopsy, influences treatment decisions and prognosis for various types of dog cancers like mast cell tumors, soft tissue sarcomas, and melanomas. Dr. Britton shares her expertise in interpreting pathology reports and navigating the nuances of cancer care for your beloved pet. Topics Covered:  What is the mitotic index?  How pathologists calculate and report mitotic index.  When mitotic index is critical for treatment decisions.  The role of biopsies in cancer diagnosis and care.  Why tumors behave unpredictably and what that means for your dog.  Key Takeaway:  The mitotic index is just one of many factors in dog cancer care, but it can play a vital role in understanding tumor behavior and guiding treatment.  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Links:  An article on mitotic index: https://www.dogcancer.com/articles/diagnosis-and-medical-procedures/mitotic-index/  Chapters:  00:00 Introduction  00:30 What is Mitotic Index?  01:30 How Mitotic Index Is Calculated   03:00 Tumor Heterogeneity   07:00 Mitotic Index and Prognosis   11:00 High vs. Low Mitotic Index   15:00 Biopsy and Treatment Decisions   19:00 Re-Biopsy Insights   21:00 Wrap-Up    Get to know Dr. Brooke Britton: https://www.dogcancer.com/people/brooke-britton-dvm-dacvim-oncology/  For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Bill Morice is the President and CEO of Mayo Clinic Labs and a professor of pathology at Mayo Clinic. Returning to the program for two segments, here he discusses liquid biopsies, their efficacy and how they'll change detecting and treating cancer. And what do humans need to be concerned over with avian influenza... or, bird flu. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Can a urine test reduce unnecessary prostate biopsies?

 I recently had the chance to join Dr. DeAngelo Webster on the Practice Biopsy podcast to talk about leadership in dentistry—what it is, what it isn't, and how anyone can step into it, title or not. We discussed how great leaders multiply impact, why trust is the foundation of influence, and how the TEACH model helps create systematic, measurable growth. Whether you're leading a practice, a team, or just yourself, this conversation breaks down leadership into real, actionable steps. Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/matrika/funk-style - License code: KUYOIZCBFCF1FOMP https://uppbeat.io/t/roo-walker/bolt - License code: RS1AU6Y5DGD5A3H8.

If you've tried everything to heal chronic Lyme, fatigue, or stubborn health issues but still feel stuck, the problem isn't you. It's that conventional medicine often misses the invisible root causes: trapped emotions, EMF toxicity, and energy blockages.  Dr. Michael Rankin Sr., a naturopathic doctor and bioenergetics pioneer, shares why nothing should last more than six months if you're asking the right questions. With over 40 years in holistic health, Dr. Rankin reveals how bioenergetic scans, PEMF therapy, and emotional detox can reverse conditions mainstream doctors call “incurable.” From dissolving bone spurs to healing insomnia, his clinic uses modern tech like BioResonance and ZYTO to map the body's energy field—no invasive tests needed.   “If you have a condition for more than six months, someone's not asking the right questions. Nothing lasts more than six months.” ~ Dr. Michael Rankin Sr.   In This Episode: - Dr. Rankin's journey into bioenergetics - Bioenergetic scans vs. blood tests: Which reveals more? - How bioenergetic testing works - Biopsies, and other hidden health bombs - Detoxing the liver and regenerating Tissues - Why root canals and scars may be blocking your healing - How radionics and bioresonance can improve sleep - PEMF devices and grounding - The Infinity Bed: deep sleep and beyond - The magic of PEMF and QRS devices - Castor oil: the detox protocol you're missing - QRS PEMF mats and how they work - The power of positive affirmations For more information, visit https://www.myersdetox.com    Ready to detox heavy metals? Take the quiz: http://www.heavymetalsquiz.com    Resources Mentioned in This Episode: - QRS PEMF Mat: Get a discount at https://testingcancer.com. - Puori PW1 Whey Protein: Get 20% off today! Visit https://puori.com/Wendy and enter code WENDY at checkout. - Chef's Foundry P600 Cookware: Get an exclusive discount today! Visit https://bit.ly/MyersDetox to claim your special offer. Dr. Jockers Functional Nutrition Podcast: Search "Dr. Jockers" on your favorite podcast platform: https://podcasts.apple.com/us/podcast/dr-jockers-functional-nutrition/id1497791107    About Dr. Michael Rankin Sr. Dr. Michael Rankin Sr. is a naturopathic doctor and director of the Kelly Metabolic Center. With decades of experience in bioenergetic medicine, he specializes in resolving emotional trauma, cancer, and chronic pain using non-invasive technologies like BioResonance, ZYTO, and PEMF therapy. A former conventional medic turned holistic pioneer, Dr. Rankin's work bridges ancient wisdom and modern science—proving that energy, not drugs, holds the key to lasting healing. His clinic offers remote bioenergetic scans and personalized protocols to detox scars, reverse calcification, and restore vitality. Learn more about Dr. Rankin at https://testingcancer.com/    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Click here to receive today's free gift on the Radio Page: The Parable of the Prodigal Son – Enjoy compelling life applications and relevant lessons on grace, anger, and compassion. The Parable of the Prodigal Son tackles issues we all face today, and is perfect for new Christians wanting to study God's grace and forgiveness to all, and anyone needing a fresh reminder of the grace Christians are called to extend to all. Use the coupon code: RADIOGIFT for free shipping!*Limit one copy per person* --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

In this episode of the Radiology Podcast, Dr. Lauren Kim speaks with Dr. Lama Dawi about a groundbreaking study comparing liquid biopsy and CT imaging in assessing tumor burden. They explore the strengths, limitations, and future of liquid biopsy in cancer diagnostics and precision medicine. Can it replace CT scans? Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases. Dawi et al.Radiology 2024; 313(2):e232674. 

Hour 3--J&J Show Monday 2/3/25-- 92.9 FM ESPN full biopsy on the Luka Doncic Trade with J&J + Jaren Jackson Jr ascension is real & happening on 92.9 FM ESPN full 2484 Mon, 03 Feb 2025 20:11:02 +0000 HyGjY9DncmZk0VsNx1nHMoZG7O71w4Iq sports Jason & John sports Hour 3--J&J Show Monday 2/3/25-- 92.9 FM ESPN full biopsy on the Luka Doncic Trade with J&J + Jaren Jackson Jr ascension is real & happening on 92.9 FM ESPN Local columnists and hoops insiders Jason Smith and John Martin appear daily 11am - 2pm on 929FM ESPN/680AM! 2024 © 2021 Audacy, Inc. Sports False https://player.amperwavepodcasting.com?feed-link=https%3A%2F%2Frss.amperwave.net%

More than a million breast biopsies are performed annually in the United States, according to the Agency for Healthcare Research and Quality. The need to ensure diagnostic accuracy is great. Alycen Wiacek, Ph.D., motivated by the impact breast cancer has had on her family and a desire to make a difference, is conducting research to help make biopsies more accurate through engineering and augmented reality. In this episode of Further Together, host Matthew Underwood talks to Wiacek about her research. Wiacek is an assistant professor at Oakland University. In her lab, the Medical Acoustics for Global Health Imaging and Clinical Translation (MAGIC), she and her students are developing a system that integrates various imaging modalities into AR to assist in the targeted biopsy of breast masses. This approach with AR means images and information can be displayed directly in the physician's field of view to better guide the biopsy process. Her research is supported by an ORAU Ralph E. Powe Junior Faculty Enhancement Award in partnership with the Augmented Reality for Enterprise Alliance (AREA).

To book a session with Dr. Lederman: http://connectionDocs.com To order the breathing device to help anxiety: https://webekalm.com/discount/ChefAJ Breaking The Silence: Sharing My Lung Cancer Diagnosis With You https://www.youtube.com/watch?v=36XThEsfLCg&t=1831s Home From the Hospital: My Lung Biopsy Adventure https://www.youtube.com/watch?v=Z1qlb9hwiLk&t=2763s https://www.youtube.com/watch?v=vQd0NcmQZSc&t=3s https://www.youtube.com/watch?v=vQd0NcmQZSc&t=3s ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. BIO: Matthew Lederman, MD, is a board-certified Internal Medicine Physician and a pioneering thought leader in holistic health. Renowned for his innovative integration of plant-based nutrition, Nonviolent Communication (NVC), trauma-informed care, and lifestyle medicine, Dr. Lederman's work highlights the profound interconnectedness of physical, emotional, and relational well-being. AI Connection Coach: http://kinectin.com Book: “WELLNESS TO WONDERFUL: 9 Pillars for Living Healthier, Longer, and with Greater Joy” https://a.co/d/6GfDdcL Social Media: Instagram: https://www.instagram.com/TheConnectionDocs Substack Newsletter: https://connectionDocs.substack.com Facebook: https://www.facebook.com/connectionDocs X: https://x.com/connectionDocs

Hi Friends, I just got home from the hospital. I had a core needle biopsy today to assess my lung tumor in order to stage my cancer. I do have a slight pneumothorax and some pain but nothing I can't handle. If you want to know about how I was diagnosed with Stage 3 Lung Cancer watch here: https://www.youtube.com/watch?v=36XThEsfLCg&t=1859s and here: https://www.youtube.com/watch?v=vQd0NcmQZSc&t=62s If you'd like to be coached by Susanna: https://susannahallhealthcoaching.com/ If you'd like to watch my FREE upcoming series Thriving in The Face of Cancer be sure you are on my mailing list: https://chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes.

In this AANEM podcast, Dr. Andrés De León interviews neuromuscular pathology experts Dr. Aziz Shaibani and Dr. Marcus Pinto about the current state and value of muscle and nerve biopsies in clinical practice. The discussion covers essential topics including proper indications for biopsies, technical considerations in choosing biopsy sites, staining techniques, and the impact of advancing genetic testing on diagnostic approaches. Dr. Shaibani emphasizes that while genetic testing has reduced some muscle biopsy indications, biopsies remain crucial for certain conditions like inflammatory myopathies and mitochondrial disorders. Dr. Pinto details specific scenarios where nerve biopsies are invaluable, particularly in diagnosing vasculitic neuropathy and amyloidosis. Both experts share insights on the complementary role of muscle and nerve biopsies in conditions like systemic vasculitis and discuss how modern diagnostic tools like myositis antibody testing and genetic panels are changing but not eliminating the need for tissue diagnosis.

It might be time to rethink your liver biopsy technique. Transfemoral transcaval core-needle liver biopsy has demonstrated key advantages over the transjugular approach and has become increasingly popular in recent years. Interventional radiologists Dr. Jacob Cynamon and Dr. Kapil Wattamwar join host Dr. Sabeen Dhand to discuss the inception and advantages of their novel approach. --- This podcast is supported by: Reflow Medical https://www.reflowmedical.com/ --- SYNPOSIS The doctors start with how they began using the transfemoral transcaval approach, along with the literature they published following adoption of this novel technique shortly thereafter. Dr. Cynamon and Dr. Wattamwar then go on to discuss the technique in detail, providing a thorough step-by-step and pausing to mention key considerations. The episode concludes with the doctors emphasizing the safety and efficacy of the transfemoral transcaval approach, citing specific findings and sharing exemplary cases. --- TIMESTAMPS 00:00 - Introduction 05:47 - Percutaneous vs. Transvenous Biopsies 08:56 - Evolution of Transfemoral Biopsies 12:41 - Comparing Transjugular and Transfemoral Approaches 24:52 - Pre-Procedural Imaging and Sheath Selection 29:23 - Complications and Case Studies 35:46 - Transcaval Biopsy Technique 45:00 - Conclusion --- RESOURCES Cynamon, 2016. Transfemoral Transcaval Core-Needle Liver Biopsy: An Alternative to Transjugular Liver Biopsy: https://pubmed.ncbi.nlm.nih.gov/26723528/ Wattamar, 2020. Transjugular versus Transfemoral Transcaval Liver Biopsy: A Single-Center Experience in 500 Cases: https://pubmed.ncbi.nlm.nih.gov/32798119/ Wattamar, 2022. The Use of the Transfemoral Transcaval Liver Biopsy Technique for Biopsies of Hepatic Masses: https://pubmed.ncbi.nlm.nih.gov/36182256/ Wattamar, 2022. Transcaval Creation of a Portal Vein Target for Transjugular Intrahepatic Portosystemic Shunt in a Patient with Portal Vein Thrombosis: https://pubmed.ncbi.nlm.nih.gov/34448032/

Certain CD4+ T-cell subtypes play a role in asthma. Characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma. Author Juan C. Celedon, MD, DrPH, University of Pittsburgh, Department of Pediatrics, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content: Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth

Hi Friends, I just got home from the hospital. I had a core needle biopsy today to assess my lung tumor in order to stage my cancer. I do have a slight pneumothorax and some pain but nothing I can't handle. If you want to know about how I was diagnosed with Stage 3 Lung Cancer watch here: https://www.youtube.com/watch?v=36XThEsfLCg&t=1859s and here: https://www.youtube.com/watch?v=vQd0NcmQZSc&t=62s If you'd like to be coached by Susanna: https://susannahallhealthcoaching.com/ If you'd like to watch my FREE upcoming series Thriving in The Face of Cancer be sure you are on my mailing list: https://chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes.

ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Website: http://connectionDocs.com Calming device: https://webekalm.com/d Upcoming Course: http://connectionDocs.com/courses Podcast: http://webeParents.com AI Connection Coach: http://kinectin.com Book: “WELLNESS TO WONDERFUL: 9 Pillars for Living Healthier, Longer, and with Greater Joy” https://a.co/d/6GfDdcL Social Media: Instagram: https://www.instagram.com/TheConnectionDocs Substack Newsletter: https://connectionDocs.substack.com Facebook: https://www.facebook.com/connectionDocs X: https://x.com/connectionDocs BIO: Matthew Lederman, MD, is a board-certified Internal Medicine Physician and a pioneering thought leader in holistic health. Renowned for his innovative integration of plant-based nutrition, Nonviolent Communication (NVC), trauma-informed care, and lifestyle medicine, Dr. Lederman's work highlights the profound interconnectedness of physical, emotional, and relational well-being. As a certified Nonviolent Communication Trainer through the Center for Nonviolent Communication (CNVC), Dr. Lederman combines Polyvagal Theory, Somatic Awareness Principles, and Pain Reprocessing to empower individuals to heal from within. His approach helps people address the root causes of chronic health challenges, fostering emotional resilience and cultivating meaningful connections. Dr. Lederman is the co-host of the webe Parents podcast, a platform dedicated to equipping parents with tools and insights to foster emotional connection, resilience, and well-being in their families. His latest book, Wellness to Wonderful, weaves together medical science, psychology, spirituality, and life wisdom to guide individuals toward lasting health, vibrancy, peace, and joy. He has co-authored six books, including the New York Times Bestseller Forks Over Knives Plan, and was featured in the acclaimed documentary Forks Over Knives. Through these works, he has shared his transformative approach to wellness with audiences around the globe. In addition to his roles as a clinician, educator, speaker, and corporate advisor, Dr. Lederman has served as Vice President of Medical Affairs at Whole Foods Market, lectured for eCornell, and provided adjunct faculty instruction in medical schools. He also co-created the webe kälm device, designed to promote emotional regulation and soothe the nervous system. As the co-founder of Connection Docs, Dr. Lederman integrates the principles of Nonviolent Communication and emotional health with practical tools to enhance relational and self-connection. Through this groundbreaking platform, he continues to empower individuals and families to strengthen their emotional well-being and build meaningful relationships.

Don't get to the end of this year wishing you had taken action to change your business and your life.Click here to schedule a free discovery call for your business: https://geni.us/IFORABEShop-Ware gives you the tools to provide your shop with everything needed to become optimally profitable.Click here to schedule a free demo: https://info.shop-ware.com/profitabilityUtilize the fastest and easiest way to look up and order parts and tires with PartsTech absolutely free.Click here to get started: https://geni.us/PartsTechTransform your shop's marketing with the best in the automotive industry, Shop Marketing Pros! Get a free audit of your shop's current marketing by clicking here: https://geni.us/ShopMarketingPros In this episode, Lucas and David Roman are joined by Scott Hicks, an industry expert. Scott provides insights into network diagnostics, explaining the simplicity of using basic tools like a multimeter for solving most network issues. David and Scott also discuss their contrasting willingness to experiment and learn. 00:00 Wife leaves class due to inappropriate jokes.05:04 Consider change; avoid repetitive conversations.08:49 Small show rebrand became huge event success.11:59 Subaru misfire: Coil connector issue discovered.15:11 Overthinking causes unnecessary complications and mistakes.18:51 GM evolving automobile network infrastructure strategies.21:46 Tinkers for 10% performance boost without manuals.23:48 Skeptical of washing machine solutions. Limited effort.27:13 It wasn't going to fix the issue.30:51 Overseas manufacturing benefits consumers with cheap EVs.35:16 Ensuring transparency for car repair data access.36:02 Lies frustrate; protocol offers access amid constraints.39:08 Approach affects perception; manufacturers willing to collaborate.43:15 Dealers influence training content, favor resistance testing.46:10 Depopulation conspiracy for land acquisition.49:41 Saw Scott; commented on his gray hair.55:11 Biopsy and scope for potential throat cancer.56:00 George's painful diverticulitis surgery with tube.58:59 Foam roller relieves back pain effectively.

We were a podcast divided this week as we discussed an episode involving the A Team trying to rescue their old doctor from Vietnam!  Join us for the fighting, the screaming, and the swearing as we navigate the dark underbelly of a sovereign nation!Episode Title: The Island Original Airdate: November 13th, 1984Find our 2023 & 2024 Summer Series from Episodes 207-211 & 240-245Find The Airwolf Years from Episodes 96 - 189Find The Knight Rider Years from Episodes 1 - 95-----We'll be back on December 4th, to discuss The A-Team Season 3 Episode 9: Showdown! The A-Team is available to rent on Amazon Prime, Apple TV, and Fandango at Home.  But don't forget to check your local library for physical copies of the show too!-----The 80's Years Opening & Closing Theme by: Steve Corning, http://thinkfishtank.comThe 80's Years Logo Design by: Luke LarssonFollow us on Facebook: https://www.facebook.com/the80syearsInstagram: @the80syearsThreads: @the80syearsBluesky: @the80syearsTikTok: @the80syearsEmail us: letusblowyourmind@gmail.comCall our Hotline: (207) 835-1954

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how cerebral amyloid angiopathy and CAA-RI present in clinical practice and how to make a diagnosis. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

Is your microwave ablation technique up to date? Dr. Ed Kim sits down with guest-host Dr. Kavi Krishnasamy to explore cutting-edge techniques in tumor ablation, with a focus on hepatocellular carcinoma (HCC) treatment with microwave. Dr. Ed Kim is the Director of Interventional Oncology and Professor of Radiology and Surgery in the Division of Vascular and Interventional Radiology at the Mount Sinai Medical Center. --- This podcast is supported by an educational grant from: Varian, a Siemens Healthineers company https://www.varian.com/ --- SYNPOSIS The doctors discuss microwave ablation, radiation segmentectomy, and the decision-making algorithms for choosing appropriate procedures based on lesion characteristics. Dr. Kim touches on the complexities of ablation near the diaphragm and subcapsular lesions, emphasizing the impact of practitioner skill and experience on outcomes. Recent advancements in ablation technologies, software, and device-specific versus device-agnostic applications are also highlighted, along with the importance of post-contrast scans and ultrasound skills. Dr. Kim also delves into emerging technologies such as HistoSonics, augmented reality/virtual reality, and immunotherapy synergies. The doctors underscore the need for a multidisciplinary approach for optimizing patient outcomes and pushing the field toward future innovations. --- TIMESTAMPS 00:00 - Introduction 04:28 - Standardizing Ablation Algorithms 07:51 - Suboptimal Lesion Locations 13:06 - Device Selection and Properties 22:49 - Ablation Planning Software 32:53 - Real-Time Visualization 44:48 - Biopsy and Ablation Techniques 52:14 - Future of Ablation Technology --- RESOURCES Dr. Ed Kim's Publications: https://scholars.mssm.edu/en/persons/edward-kim ACCLAIM Trial: https://www.sio-central.org/ACCLAIM-Trial A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4093 Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501 SIR welcomes results of COLLISION Trial, presented at the 2024 ASCO Annual Meeting: https://www.sirweb.org/media-and-pubs/media/news-release-archive/collision-trial-06032024/ HistoSonics: https://histosonics.com/

Dr. Justin Abbatemarco talks with Dr. Ahmad Nehme about the complexities of diagnosing and differentiating between Cerebral amyloid angiopathy-related inflammation and biopsy-positive primary angiitis of the central nervous system. Read the related article in Neurology. Disclosures can be found at Neurology.org.